VLP tech may deliver better vaccines; U.S. accelerates seasonal flu production;

Vaccine Research

New vaccines being developed with virus-like particles could provide a much faster, less expensive process for designing new jabs that offer better protection from emerging threats. Report

Australian researchers are exploring a new vaccine to guard against meningococcal-B disease. "I think we're still probably three to five years away from having a licensed vaccine available for everyone," said Dr. Helen Marshall. Story

The inactivated flu vaccine does not appear to be effective in preventing influenza-related hospitalizations in children, especially the ones with asthma. In fact, children who get the flu vaccine are more at risk for hospitalization than their peers who do not get the vaccine, according to new research that will be presented on May 19, at the 105th International Conference of the American Thoracic Society in San Diego. Release

Vaccine Market

Thailand has been given approval by the WHO to use an "advanced" vax production technology for flu vaccines. The production of live attenuated vaccines will be rolled out in the event of a pandemic. Story

U.S. officials say they want to accelerate production of seasonal flu vaccines in case they decide to shift production later to the swine flu jab. Story

Health officials in Wales say they face the worst outbreak of measles they've seen in years. Report

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.